Form 4: Cryo-Cell Co-CEO Portnoy Reports Share Ownership Changes
Insider Ownership Report
Cryo-Cell International Co-CEO David Portnoy filed a Form 4 detailing changes in his beneficial ownership, including the disposition of shares previously held for a child.
Summary
- David Portnoy, Chairman and Co-CEO of Cryo-Cell International Inc. (CCEL), filed a Form 4 reporting changes in his beneficial ownership of company securities.
- On September 2, 2025, Portnoy reported the disposition of 15,611 shares of common stock, which were previously held indirectly as custodian for a daughter.
- This disposition occurred because the child reached the age of majority, resulting in the reporting person no longer having beneficial ownership of these specific shares.
- Following this transaction, Portnoy beneficially owns a total of 1,619,772 shares of common stock, held directly and indirectly through various entities including a 401K, IRA, spouse, Mayim Limited Partnership, uTIPu, Inc., PartnerCommunity, Inc., and as custodian for sons.
- Portnoy also holds 530,000 stock options with various exercise prices and vesting schedules, including 280,000 options that vest immediately if the company's common stock reaches $25.00 per share during the seven-year option term.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of insider ownership changes, with the reported disposition attributed to a non-market-related event (child reaching majority), thus having a neutral impact on company sentiment.
Positives
- The filing is a routine and transparent disclosure of insider ownership, adhering to SEC regulations.
- Significant beneficial ownership by a key executive (Chairman, Co-CEO) aligns management's interests with those of shareholders.
Negatives
- A disposition of 15,611 shares, even for a non-market-related reason, represents a reduction in the insider's direct beneficial ownership.
Future Outlook
NA
Industry Context
This Form 4 filing is a standard regulatory disclosure of insider trading activity and beneficial ownership. It does not provide broader industry context or competitive analysis.
Stakeholder Impact
- Shareholders: Provides transparency regarding a key executive's holdings and a minor, non-market-driven change in beneficial ownership.
- Management: Reflects the ongoing beneficial ownership structure of the Chairman and Co-CEO, aligning his interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 08/30/2019 | Grant date for 26,243 stock options with an exercise price of $7.53, expiring 08/30/2029. |
| 12/20/2019 | Grant date for 23,636 stock options with an exercise price of $7.28, expiring 12/20/2029. |
| 12/22/2021 | Grant date for 280,000 stock options with an exercise price of $12.27, expiring 12/22/2028. These options vest immediately if the common stock reaches $25.00 per share during the seven-year option term. |
| 12/23/2022 | Grant date for 50,000 stock options with an exercise price of $4.30, expiring 12/23/2027. |
| 01/03/2023 | Grant date for 50,000 stock options with an exercise price of $4.77, expiring 01/03/2028. Vesting schedule: 8,750 upon issuance, 8,749 on 1/2/2024, 21,000 on 1/2/2025, and 11,501 on 1/2/2026. |
| 12/22/2023 | Grant date for 50,000 stock options with an exercise price of $6.47, expiring 12/22/2028. Vesting schedule: 1/3 upon issuance, 1/3 on December 22, 2024, and 1/3 on December 22, 2025. |
| 01/21/2025 | Grant date for 50,000 stock options with an exercise price of $8.08, expiring 01/21/2030. Vesting schedule: 1/3 upon issuance, 1/3 on January 21, 2026, and 1/3 on January 21, 2027. |
| 09/02/2025 | Date of reported transaction (disposition of 15,611 shares) and filing date of the Form 4. |
Keywords
Cryo-Cell International, CCEL, David Portnoy, Form 4, insider ownership, beneficial ownership, stock options, director, CEO, 10% owner
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.